| CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 |
342 |
| CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016 |
190 |
| Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 |
63 |
| Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data |
62 |
| Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma |
45 |
| Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas |
37 |
| The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis |
35 |
| Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma |
31 |
| CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges |
30 |
| EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma |
29 |
| Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location |
29 |
| Temozolomide-associated hypermutation in gliomas |
27 |
| DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management |
26 |
| EANO guidelines for the diagnosis and treatment of ependymal tumors |
25 |
| Durable complete responses in some recurrent highgrade glioma patients treated with Toca 511+Toca FC |
25 |
| EGFR heterogeneity and implications for therapeutic intervention in glioblastoma |
25 |
| Pediatric low-grade gliomas: next biologically driven steps |
25 |
| MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges |
23 |
| A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 |
23 |
| The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study |
23 |
| Prognostic relevance of genetic alterations in diffuse lower-grade gliomas |
23 |
| The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades |
21 |
| Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation |
21 |
| Safety and efficacy of depatuxizumab mafodotin plus temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial |
21 |
| Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications |
20 |
| Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications |
20 |
| CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas |
19 |
| Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification |
19 |
| Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement |
18 |
| Characterization of single microvesicles in plasma from glioblastoma patients |
18 |
| Temozolomide for immunomodulation in the treatment of glioblastoma |
17 |
| TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma |
17 |
| Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization |
16 |
| The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal |
16 |
| Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T |
16 |
| Advances in multidisciplinary therapy for meningiomas |
15 |
| Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy |
15 |
| 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data |
15 |
| PET imaging in patients with brain metastasis-report of the RANO/PET group |
15 |
| Radiation-induced astrocyte senescence is rescued by Delta 133p53 |
15 |
| Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014 |
14 |
| Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 |
14 |
| Long-term exposure to ambient air pollution and incidence of brain tumor: the European Study of Cohorts for Air Pollution Effects (ESCAPE) |
14 |
| The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology |
14 |
| Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma |
14 |
| The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors |
14 |
| In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature |
14 |
| Molecular and translational advances in meningiomas |
13 |
| Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005 using the Central Brain Tumor Registry of the United States |
13 |
| Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma |
13 |
